GlassScriptPhysician profile
Daniel Joseph Dean
NPI 1922329754
$3,205.88
in general payments reported to CMS, 2019-2025
27 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $263 · 2024: $1,423 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,102 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,101.86 |
| Education | $104.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $361.47 | 2023-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $301.18 | 2024-2025 | Jynarque |
| Travere Therapeutics, INC. | $299.24 | 2024-2025 | Filspari |
| Amgen INC. | $274.23 | 2023-2025 | Tavneos, Krystexxa, Parsabiv |
| Novartis Pharmaceuticals Corporation | $217.60 | 2023-2025 | |
| Akebia Therapeutics INC | $213.82 | 2023-2025 | Vafseo, Auryxia |
| Vantive US Healthcare LLC | $172.23 | 2025 | |
| Ardelyx, INC. | $166.56 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.76 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $117.26 | 2023-2025 | |
| Shield Therapeutics INC | $102.28 | 2024-2025 | |
| Scpharmaceuticals INC. | $93.73 | 2025 | |
| Vifor Pharma, INC. | $87.69 | 2023-2025 | Veltassa |
| Novo Nordisk INC | $75.20 | 2023-2025 | Rybelsus, Ozempic, Rivfloza |
| Glaxosmithkline, LLC. | $71.87 | 2024-2025 | Benlysta, Shingrix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $71.27 | 2023-2025 | Injectafer |
| Lilly USA, LLC | $61.45 | 2023-2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $56.28 | 2024-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $55.91 | 2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $47.21 | 2025 | Gazyva |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.19 | 2025 | |
| Alexion Pharmaceuticals, INC. | $43.62 | 2024-2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $33.07 | 2024 | Acthar |
| Calliditas Therapeutics US INC. | $23.84 | 2025 | Tarpeyo |
| Apellis Pharmaceuticals, INC. | $21.88 | 2025 | Empaveli |
| Ascendis Pharma Endocrinology INC | $20.45 | 2025 | Yorvipath |
| Opko Pharmaceuticals, LLC | $19.59 | 2024 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.